ABSTRACT
Stemming from work on a previous clinical candidate, loviride, and other alpha-APA derivatives, a new series of potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) has been synthesized. The ITU analogues, which contain a unique diarylated imidoyl thiourea, are very active in inhibiting both wild-type and clinically important mutant strains of HIV-1.
Subject(s)
Anti-HIV Agents/chemistry , Anti-HIV Agents/pharmacology , HIV Reverse Transcriptase/antagonists & inhibitors , Imines/chemistry , Imines/pharmacology , Thiourea/chemistry , Thiourea/pharmacology , Acetamides/chemistry , Acetamides/pharmacology , Acetophenones/pharmacology , Aniline Compounds/chemistry , Anti-HIV Agents/chemical synthesis , Drug Design , Drug Evaluation, Preclinical , Drug Stability , HIV Reverse Transcriptase/drug effects , HIV Reverse Transcriptase/genetics , HIV-1/drug effects , Structure-Activity Relationship , Thiourea/analogs & derivativesABSTRACT
A synthesis program directed toward improving the stability of imidoyl thiourea based non-nucleoside reverse transcriptase inhibitors (NNRTIs) led to the discovery of diaryltriazines (DATAs), a new class of potent NNRTIs. The synthesis and anti-HIV structure-activity relationship (SAR) studies of a series of DATA derivatives are described.
Subject(s)
Anti-HIV Agents/chemistry , Anti-HIV Agents/pharmacology , HIV Reverse Transcriptase/antagonists & inhibitors , Anti-HIV Agents/chemical synthesis , Drug Design , HIV Reverse Transcriptase/genetics , HIV-1/drug effects , HIV-1/genetics , Inhibitory Concentration 50 , Reverse Transcriptase Inhibitors/chemistry , Reverse Transcriptase Inhibitors/pharmacology , Structure-Activity Relationship , Triazines/chemistryABSTRACT
The synthesis and anti-HIV-1 activity of a series of diarylpyrimidines (DAPYs) are described. Several members of this novel class of non-nucleoside reverse transcriptase inhibitors (NNRTIs) are extremely potent against both wild-type and a panel of clinically significant single- and double-mutant strains of HIV-1.
Subject(s)
Anti-HIV Agents/chemistry , Anti-HIV Agents/pharmacology , Nitriles/chemistry , Nitriles/pharmacology , Pyrimidines/chemistry , Pyrimidines/pharmacology , Drug Evaluation, Preclinical , HIV Reverse Transcriptase/antagonists & inhibitors , HIV Reverse Transcriptase/drug effects , HIV Reverse Transcriptase/genetics , HIV-1/drug effects , HIV-1/genetics , Inhibitory Concentration 50 , Mutation , Reverse Transcriptase Inhibitors/chemistry , Reverse Transcriptase Inhibitors/pharmacology , Structure-Activity RelationshipABSTRACT
A series of 4-substituted imidazole sulfonamides has been prepared by solid-phase chemistry. These compounds were found to have good in vitro antifungal activity and constitute the first examples of C-linked azoles with such activity. The most potent inhibitor (30) demonstrated inhibition of key Candida strains at an in vitro concentration of < 100nM and compared favorably with in vitro potency of itraconazole.
Subject(s)
Antifungal Agents/chemical synthesis , Antifungal Agents/pharmacology , Candida/drug effects , Combinatorial Chemistry Techniques , Imidazoles/chemical synthesis , Imidazoles/pharmacology , Antifungal Agents/chemistry , Drug Design , Ergosterol/biosynthesis , Fungi/drug effects , Imidazoles/chemistry , Microbial Sensitivity Tests , Molecular Structure , Structure-Activity RelationshipABSTRACT
4,5,6,7-Tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2(1 H)-ones (TIBO), 1, have been shown to significantly inhibit HIV-1 replication, as reported in detail in our prior publications. Since our earlier reports, we have modified the TIBO structures 1 by removing the 5-membered ring of 1, generating 1,3,4,5-tetrahydro-2H-1,4-benzodiazepin-2-ones (TBO), 4, a bicyclic series of compounds. Although compounds 4 possess modest activity when compared to TIBO analogues 1, they clearly demonstrated significant anti-HIV-1 activity.
Subject(s)
Anti-HIV Agents/chemical synthesis , Benzodiazepinones/chemical synthesis , HIV-1/drug effects , Imidazoles/chemical synthesis , Anti-HIV Agents/pharmacology , Benzodiazepinones/pharmacology , Cells, Cultured , Humans , Imidazoles/pharmacology , Structure-Activity RelationshipABSTRACT
We recently reported on a series of pyrrole Mannich bases orally active in inhibiting the conditioned avoidance response (CAR) in rats. These compounds exhibit affinity for both D2 and 5-HT1A receptors, and some are noncataleptogenic. Such a profile suggests that they may be potential antipsychotic agents which lack the propensity for causing extrapyramidal side effects and tardive dyskinesias in humans. One of these compounds, 1-[[1-methyl-5-[[4-[2-(1-methylethoxy)phenyl]- 1-piperazinyl]methyl]-1H-pyrrol-2-yl]methyl]-2-piperidinone (RWJ 25730, 1), was chosen for further development but found to be unstable in dilute acid. In order to improve stability, we replaced the pyrrole methylene linkage to the piperazine ring with ethylene, employed ethylene and dicarbonyl as linkers between the lactam and the pyrrole ring, placed electron-withdrawing groups on the pyrrole ring, and substituted acyclic amide for lactam. In addition, we replaced the pyrrole segment with other heterocycles including thiophene, furan, isoxazole, isoxazoline, and pyridine. Generally, replacement of the N-methylpyrrole segment with thiophene, furan, isoxazoline, or pyridine afforded compounds equipotent with 1 in CAR, which were more stable in dilute acid. In the case of side chain or lactam modifications, CAR activity was significantly decreased or abolished, with the exception of 6. For the most part, the modifications to 1 resulted in the decrease or loss of D2 receptor binding. However, within this series, 5-HT1A receptor binding was greatly increased, with thiophene 40 exhibiting an IC50 of 0.07 nM. The CAR activities of pyrroles 6 and 12, thiophene 40, furans 44-47, isoxazolines 49 and 50, and pyridine 54 coupled with their weak or nonexistent D2 binding and strong 5-HT1A binding suggest that they may be acting via a nondopaminergic mechanism or that dopaminergic active metabolites are responsible. Pyrrole 6 and furans 44 and 47 show promise as antipsychotic agents based on their CAR activity, receptor-binding profile, and solution stability.
Subject(s)
Antipsychotic Agents/chemistry , Azepines/chemistry , Azocines/chemistry , Furans/chemistry , Piperazines/chemistry , Piperidones/chemistry , Animals , Avoidance Learning/drug effects , Azepines/metabolism , Azepines/pharmacology , Azocines/metabolism , Azocines/pharmacology , Cell Membrane/metabolism , Cerebral Cortex/metabolism , Conditioning, Psychological/drug effects , Drug Stability , Furans/metabolism , Furans/pharmacology , Hydrogen-Ion Concentration , Male , Molecular Structure , Piperazines/metabolism , Piperazines/pharmacology , Piperidones/metabolism , Piperidones/pharmacology , Rats , Rats, Inbred F344 , Rats, Wistar , Receptors, Dopamine D2/metabolism , Receptors, Serotonin/metabolism , Structure-Activity RelationshipABSTRACT
In previous papers, we have described the discovery of a new series of compounds, 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2(1 H)- ones, TlBO (1 and 1a), with potent anti-HIV-1 activity and the synthesis of analogues to better define the structure-activity relationships (SAR) in terms of changes in substituents at the N-6 position and variations of the five-membered urea ring as well as the seven-membered diazepine ring. This paper describes the synthesis of TlBO analogues with various substitutents on the aromatic ring and their SAR in terms of anti-HIV-1 properties. Substituents on the 8-position furnished the most rewarding results and gave a large improvement in potency versus the parent compound. These included halogen, thiomethyl, and methyl. Analogues like 8-cyano, -methoxy, and -acetylene were equipotent, while 8-amino, -acetylamino, -dimethylamino, and -nitro were inactive (Table 1). Substituents at the 9-position tended to have little effect on activity, and 10-substituents decreased activity. The 8-chloro compound 6a with IC50 = 0.0043 microM is currently under clinical development.
Subject(s)
Antiviral Agents/chemical synthesis , Benzodiazepines/chemical synthesis , Benzodiazepines/pharmacology , HIV-1/drug effects , Imidazoles/chemical synthesis , Imidazoles/pharmacology , Antiviral Agents/pharmacology , Cell Line , Cytopathogenic Effect, Viral/drug effects , Structure-Activity Relationship , Virus Replication/drug effectsABSTRACT
4,5,6,7-Tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2 (1H)-ones (TIBO), 1, have been shown to significantly inhibit HIV-1 replication in vitro by interfering with the virus's reverse transcriptase enzyme. They have also demonstrated potential clinical efficacy in combating HIV-1, on the basis of a preliminary study. Our prior publications have discussed the discovery of this series of compounds and reported some preliminary chemical and biological studies around N-6 substitutions and 5-membered ring variations of 1. This manuscript describes our synthetic endeavors around 4, 5, and 7 mono- and disubstitutions of 1 and discusses related HIV-1 inhibitory structure-activity relationships. On the basis of inhibition of HIV-1's cytopathic effects in MT-4 cells, we found that 5-mono-Me-substituted analogues, the original substitution in the early lead compounds, and 7-mono-Me-substituted analogues of 1 were comparable as being consistently the most active compounds. Although generally less active, the 4,5,7-unsubstituted, 4-mono-substituted, cis- and trans-5,7-di-Me-substituted, and cis-4,5-di-Me-substituted analogues of 1 also exhibited some significant desired activity. The remaining trans-4,5-di-Me-substituted, cis- and trans-4,7-di-Me-substituted, and all 4,5-, 5,6-, 6,7-, and 7,8-fused disubstituted analogues of 1 possessed no noticeable desired activity.
Subject(s)
Antiviral Agents/chemical synthesis , Benzodiazepines/chemical synthesis , Benzodiazepines/pharmacology , HIV-1/drug effects , Imidazoles/chemical synthesis , Imidazoles/pharmacology , Antiviral Agents/pharmacology , Cell Line , Structure-Activity Relationship , Virus Replication/drug effectsABSTRACT
Tetrahydro-imidazo[4,5,1-jk][1,4]-benzodiazepin-2(1H)-one and -thione (TIBO) derivatives were shown to specifically block human immunodeficiency virus type 1 (HIV-1) replication through a unique interaction with the HIV-1 reverse transcriptase (RT). Through further modification of the lead compounds and structure-activity relationship analysis several new TIBO derivatives that show high potency, selectivity, and specificity against HIV-1 have been obtained. A new TIBO derivative, R86183, inhibits the replication of HIV-1, but not HIV-2, in a variety of CD4+ T-cell lines and peripheral blood lymphocytes, at a concentration of 0.3 to 30 nM, which is at least 4 orders of magnitude lower than the 50% cytotoxic concentration. Whereas an HIV-1 strain containing the Leu-100-->Ile mutation in the RT gene is about 400-fold less susceptible, R86183 still inhibits the replication of an HIV-1 strain containing the Tyr-181-->Cys RT mutation by 50% at a concentration of 130 nM. R86183 inhibits the poly(C).oligo(dG)12-18-directed HIV-1 RT reaction by 50% at a concentration of 57 nM. The antiviral activity of 22 TIBO derivatives in cell culture correlated well with their activity against HIV-1 RT. No such correlation was found for their cytotoxicity. The combination of R86183 with either zidovudine or didanosine resulted in a synergistic inhibition of HIV-1 (strain IIIB) replication. Combination of R86183 with the protease inhibitor Ro31-8959 was found to be additive. Also described is a dilution protocol circumventing overestimation and underestimation of antiviral activity due to adherence to plastic surfaces.
Subject(s)
Antiviral Agents/pharmacology , Benzodiazepines/pharmacology , Didanosine/pharmacology , HIV-1/drug effects , Virus Replication/drug effects , Zidovudine/pharmacology , Drug Synergism , HIV Reverse Transcriptase , Imidazoles/pharmacology , Reverse Transcriptase Inhibitors , Structure-Activity RelationshipABSTRACT
Nitrogen heterocyclic carboximidamides, such as linogliride, 1a, have been shown to possess significant hypoglycemic activity and have shown clinical efficacy as potential antidiabetic agents. We evaluated the biological significance of the heterocyclic ring A of general structure 1, which has always been maintained in this class of compounds, by preparing acyclic compounds of general structure 2. Preliminary in vivo biological testing, i.e., the glucose tolerance test in rats, indicates that a number of the specific acyclic carboximidamides prepared, 6a-kk, possessed significant hypoglycemic activity often comparable to, and in some cases better than, the activity noted for our model compound, 1a. These results suggest that the heterocyclic ring A of 1 is not essential for hypoglycemic activity for this class of compounds.
Subject(s)
Amides/chemical synthesis , Hypoglycemic Agents/chemical synthesis , Imides/chemical synthesis , Amides/pharmacology , Animals , Glucose Tolerance Test , Hypoglycemic Agents/pharmacology , Imides/pharmacology , Rats , Structure-Activity RelationshipABSTRACT
Recently, we reported on a series of arylpiperazines 4 which exhibit high affinity for the serotonin 5-HT-1A and 5-HT-1B binding sites. Although these compounds interact weakly with dopamine D-1 and D-2 receptors, they are reasonably potent in inhibiting conditioned avoidance responding (CAR) in the rat, an indication of potential antipsychotic activity. Conversion of these arylpiperazines to pyrrole Mannich bases has provided a series of compounds (10-44) which exhibit potent inhibition of CAR when given po and have strong affinity for both the D-2 and 5-HT-1A binding sites. Some of these agents also fail to produce catalepsy. The D-2 binding data and the block of CAR suggest that they are potential antipsychotic agents and the lack of cataleptogenic potential suggests some might possess less liability for producing extrapyramidal side effects and tardive dyskinesias in man.
Subject(s)
Antipsychotic Agents/pharmacology , Mannich Bases/pharmacology , Animals , Antipsychotic Agents/chemical synthesis , Avoidance Learning/drug effects , Male , Mannich Bases/chemical synthesis , Rats , Rats, Inbred Strains , Receptors, Dopamine/drug effects , Receptors, Dopamine/metabolism , Receptors, Dopamine D2 , Receptors, Serotonin/drug effects , Receptors, Serotonin/metabolism , Structure-Activity RelationshipABSTRACT
In the first paper of this series a new structure with anti-HIV-1 activity was disclosed and analogues were synthesized to explore the structure-activity relationship of changes in the substituent (R) attached at the N-6 position of 9. This study describes the syntheses and anti-HIV-1 testing of analogues with variations of the five-membered urea ring of the 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk] [1,4]benzodiazepin-2(1H)-one (TIBO) structures. Although many different rings were synthesized to replace the cyclic urea of TIBO, most were found to be inactive in inhibiting the replication of the HIV-1 virus in MT-4 cells. The exceptions were replacement of the urea oxygen with sulfur or selenium to give the corresponding thio- or selenoureas. These were found to be more active than the oxygen counterparts. A small series of analogues was synthesized and tested which allowed direct comparison of urea and thiourea derivatives. Without exception, the latter were always more active than the former. The most active compound of this series (8d) was found to inhibit the HIV-1 virus with an IC50 of 0.012 microM which is comparable to that of AZT.
Subject(s)
Antiviral Agents/chemical synthesis , Benzodiazepines/chemical synthesis , Imidazoles/chemical synthesis , Antiviral Agents/pharmacology , Benzodiazepines/pharmacology , HIV-1/drug effects , Imidazoles/pharmacology , Microbial Sensitivity Tests , Structure-Activity Relationship , Virus Replication/drug effectsABSTRACT
A series of 6-substituted 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin- 2(1H)-ones (9) have been synthesized and tested for their ability to inhibit the replication of the HIV-1 virus in MT-4 cells. Two synthetic methods are described, one of which allows the synthesis of single enantiomers of the final products. A structure-activity study was done within the series of compounds to determine the optimum group for the 6-position substitution and to determine whether the activity was enantiospecific at the 5-position, which was substituted with a methyl group. The best analogue, 9jj, inhibited HIV-1 with an IC50 of 4 microM, which is comparable to the activity level of DDI, a 2',3'-dideoxynucleoside-type structure undergoing clinical trials as an anti-AIDS therapy.
Subject(s)
Antiviral Agents/chemical synthesis , Benzodiazepinones/chemical synthesis , HIV/drug effects , Antiviral Agents/pharmacology , Benzodiazepinones/pharmacology , Chemical Phenomena , Chemistry , Structure-Activity Relationship , Virus Replication/drug effectsABSTRACT
In the search for compounds active against human immunodeficiency virus (HIV), we have found that members of a novel series of tetrahydro-imidazo[4,5,1-jk][1,4]-benzodiazepine-2(1H)-one and -thione (TIBO) derivatives inhibit the replication of HIV-1, the main aetiological agent of AIDS, but not of HIV-2, or of any other DNA or RNA viruses. In five cell systems, HIV-1 is inhibited by TIBO derivatives in nanomolar amounts, which are 10(4)-10(5) times lower than the cytotoxic concentration. The unprecedented specificity of these compounds may be due to an interaction with a reverse transcriptase-associated process. By contrast, AZT (3'-azido-2',3'-dideoxythymidine), which is used for the treatment of AIDS, and DDC (2',3'-dideoxycytidine) and DDI (2',3'-dideoxyinosine), whose clinical application is being assessed, inhibit both HIV-1 and HIV-2 at concentrations that, depending on the cell systems, are 2 to 4 orders of magnitude below their cytotoxic concentration. TIBO-derivatives are new chemicals unrelated to any other antiviral agents. We believe that they are the most specific and potent inhibitors of HIV-1 replication studied so far.
Subject(s)
Antiviral Agents , Benzodiazepines/pharmacology , HIV-1/physiology , Imidazoles/pharmacology , Virus Replication/drug effects , Animals , Benzodiazepines/chemical synthesis , CD4-Positive T-Lymphocytes/microbiology , Cell Line , Cytopathogenic Effect, Viral/drug effects , Didanosine/pharmacology , Dogs , HIV-2/physiology , Humans , Imidazoles/chemical synthesis , Lymphocytes/microbiology , Molecular Conformation , Molecular Structure , Reverse Transcriptase Inhibitors , Zidovudine/pharmacologyABSTRACT
Dihydropyridines with 1,4,4-trisubstitution were synthesized and tested for antihypertensive activity in a spontaneously hypertensive rat model. This substitution pattern on the dihydropyridine nucleus differs markedly from that found most active in the structure-activity relationship established for nifedipine-like compounds. However, some were found to significantly lower blood pressure at testing doses (30 mg/kg, ip and 100 mg/kg, po) for up to 24 h. Methyl 1,4-dihydro-4,4-dimethyl-1-pyridinepropanoate (2-1), for example, lowered blood pressure 71 mmHg at 30 mg/kg, ip and the effect endured for greater than 24 h. Unlike prototypical dihydropyridines such as nifedipine, these compounds did not seem to have any effect on calcium channels.
Subject(s)
Antihypertensive Agents , Dihydropyridines/therapeutic use , Animals , Chemical Phenomena , Chemistry , Dihydropyridines/chemical synthesis , Hypertension/drug therapy , Molecular Structure , Rats , Rats, Inbred SHR , Structure-Activity RelationshipABSTRACT
All four possible stereoisomers of cyclo(histidylproline) were individually synthesized, purified, and characterized. They were each tested for anorectic activity in rats with a free feeding paradigm over 24 h. Contrary to literature reports, none significantly reduced food intake at any time over the test period.
Subject(s)
Eating/drug effects , Peptides, Cyclic/pharmacology , Piperazines/pharmacology , Animals , Bombesin/pharmacology , Chemical Phenomena , Chemistry , Kinetics , Male , Peptides, Cyclic/chemical synthesis , Piperazines/chemical synthesis , Rats , Rats, Inbred Strains , StereoisomerismABSTRACT
A number of molecular similarities between the antipsychotic agents butaclamol and clozapine were noted. Based on the premise that this was a strong indicator of a common mechanism of action (i.e., binding at the antagonist state of the dopamine receptor), a research approach was described. Three simplified analogues (4,8, and 12a) of butaclamol which still retained the molecular functionalities of the parent structure were synthesized and tested in the haloperidol receptor assay. 1-(5-Methyl-10, 11-dihydro-5H-dibenzo[a,d]cycloheptene)-4-tert-butyl-4-piperidine (12a) displaced tritiated haloperidol with an IC50 value of 2.4 nM, as compared to a value of 0.5 nM for butaclamol However, when 12a was tested in vivo or in the spiroperidol receptor assay it was found to be considerably less potent.
Subject(s)
Antipsychotic Agents/chemical synthesis , Butaclamol/analogs & derivatives , Dibenzocycloheptenes/analogs & derivatives , Animals , Antipsychotic Agents/adverse effects , Avoidance Learning/drug effects , Butaclamol/chemical synthesis , Butaclamol/metabolism , Butaclamol/pharmacology , Cattle , Clozapine/pharmacology , Dextroamphetamine/antagonists & inhibitors , Dextroamphetamine/toxicity , Humans , In Vitro Techniques , Male , Mice , Receptors, Dopamine/metabolism , Stereotyped Behavior/drug effectsABSTRACT
The title compounds (most notably 2a) were synthesized on the basis of the N-methylation hypothesis of schizophrenia. They were evaluated in dopamine and haloperidol receptor assays. The binding characteristics were comparable in some cases to known neuroleptics.